The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

This study investigated patients with primary lung cancer who received PET/CT scan, a medical imaging test, and subsequently ...

Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a serious ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Addition of the immunotherapy drug pembrolizumab to standard of care ... Duke University and Princess Margaret Cancer Centre, University Health Network. The findings, published today in The Lancet, ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...

For the treatment of glioblastoma, immunotherapy represents a promising, though complex, avenue. Due to the tumour’s highly ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...

Researchers think they’ve figured out why cancer treatments that harness a person’s immune system to fight a tumor can ...

TIL-Tregs specifically increase GLUT3 expression for glucose uptake in tumors. - GLUT3 fuels protein O-GlcNAcylation, ...